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Most cancer deaths occur due to
metastatic spread. Although much is now
known about how tumors initiate, our
understanding of the complex process of
tumor metastasis remains frustratingly
vague, despite intense scientific endeav-
or. Normal cellular behaviors, such as
survival, adhesion, and migration/inva-
sion, are thought to be exploited by
tumor cells as they metastasize
(Bernards and Weinberg,
2002; Hynes, 2003 and refer-
ences therein). However, few
individual molecules that are
known to be involved in
these cellular processes
have been directly implicated
in tumor metastasis.
Two recent papers pro-
vide strong evidence that the
membrane:cytoskeleton orga-
nizer Ezrin promotes tumor
metastasis (Khanna et al.,
2004; Yu et al., 2004).
Together with previous work,
these two studies firmly
establish that high levels of
Ezrin expression are linked 
to metastatic behavior in 
different types of tumors from
diverse species.Furthermore,
both groups provided experi-
mental validation of a
prometastatic function for
Ezrin.
The ERM proteins (Ezrin,
Radixin, and Moesin) and
Merlin are closely related
members of the band 4.1
superfamily of proteins that, when activat-
ed, interact with both membrane proteins
and the actin cytoskeleton (Bretscher et
al., 2002). By organizing membrane-
cytoskeleton-associated complexes and
creating specialized membrane domains,
the ERM proteins regulate cellular activi-
ties such as survival, adhesion, and
migration/invasion, all of which are impor-
tant during tumor development and 
progression (Bretscher et al., 2002;
McClatchey, 2003). Several studies sug-
gest an important functional relationship
between the ERM proteins and the small
GTPase Rho, which controls actin
cytoskeleton remodeling and related cel-
lular activities. Rho-dependent phosphor-
ylation of the ERM carboxyl-terminus
constitutes the best-known mechanism of
ERM activation; the ERM proteins, in turn,
can regulate Rho (Bretscher et al., 2002;
McClatchey, 2003).
A powerful strategy for identifying
novel metastasis-associated genes and
gene expression patterns is DNA
microarray analysis, which facilitates
the identification of genes that con-
tribute to metastasis through epigenetic
changes in expression rather than
through direct genetic mutation. Indeed,
both Yu et al. and Khanna et al. began
by utilizing microarray analysis to identi-
fy gene expression patterns that were
specific to highly versus poorly
metastatic derivatives of murine tumor
cell lines (Khanna et al., 2001, 2004; Yu
et al., 2004). They found that Ezrin was
significantly overexpressed in highly
metastatic murine rhabdomyosarcoma
(RMS) and osteosarcoma (OSA) cell
lines relative to their poorly metastatic
counterparts. Importantly, they deter-
mined that Ezrin inhibition by stable
expression of short hairpin RNA or anti-
sense constructs directed at
Ezrin, or an established
dominant negative Ezrin
mutant significantly reduced
the metastatic capability of
cell lines in both models.
Conversely, overexpression
of wild-type Ezrin conferred
higher metastatic capability
to nonmetastatic RMS cells.
Finally, both groups extend-
ed their findings to other
species, demonstrating clear
correlations between high
Ezrin levels and both
increasing RMS grade in
humans and poor OSA prog-
nosis in dogs and human
children. These data, togeth-
er with the work of others,
provide compelling evidence
for a metastasis-promoting
function of Ezrin (Nestl et al.
2001).
Is Ezrin a metastasis-spe-
cific gene? What is a metasta-
sis-specific gene? It has been
recently argued that specific
“metastasis genes” might not
exist, given that their mutation would not
confer a proliferative advantage to the
primary tumor. Instead, the metastatic
phenotype may arise after a specific
combination of genetic mutations accu-
mulates, regardless of the sequence 
of their occurrence (Bernards and
Weinberg, 2002). Alternatively, genetic
or epigenetic changes that do not confer
a proliferative advantage but specifically
favor metastasis are possible. Evidence
for both models exists, and both may
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The insidious process of tumor metastasis is the most devastating and least well-understood aspect of cancer. Metastasis
is very complex and employs many cellular processes, suggesting that individual metastatic determinants may not be eas-
ily identified. Mounting evidence, culminating in the work described in two recent articles, strongly suggests that the mem-
brane:cytoskeleton organizer Ezrin can promote tumor metastasis (Khanna et al., 2004;Yu et al., 2004). Ultimately, a better
understanding of exactly how Ezrin confers metastatic advantage will provide important insight into this key problem in
cancer biology.
Figure 1: A well-established osteosarcoma metastasis in the lung of an
Nf2+/− mouse
OSM, osteosarcoma metastasis; L, lung parenchyma. Note the
boundary between the metastasis and lung parenchyma (*). Here,
osteoid cells survive, proliferate, and migrate into a foreign milieu.
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contribute to metastasis in the same sys-
tem (Hynes, 2003). In fact, although
Ezrin function has been previously linked
to metastatic behavior, a direct role for
any of the ERM proteins in regulating cell
proliferation has not been reported to
date (Bretscher et al., 2002; McClatchey,
2003 and references therein). Indeed,
Ezrin levels appear to have no effect on
the growth properties of the cells used in
either study. In addition, Yu et al. showed
that Ezrin expression progressively
increases with advancing stages of
human RMS. Collectively, these data
argue for a prometastatic function for
Ezrin specifically in late tumor progres-
sion and metastasis.
So, what advantage could Ezrin
overexpression confer in the late
metastatic steps of tumor progression?
Using an experimental tail vein injection
model of metastasis, Khanna et al. found
that reducing Ezrin expression led to
decreased survival of GFP-labeled high-
ly metastatic OSA cells that reached the
lung. During this rate-limiting stage of
metastasis, cells must survive individual-
ly, proliferate, and utilize cell:cell and/or
cell:extracellular matrix (ECM) adhesion
to attach to and invade between
endothelial cells (extravasate) and into
the lung parenchyma—all in an environ-
ment to which they are not programmed
(Figure 1). Reduced Ezrin expression
was accompanied by reduced levels of
active MAPK and Akt, which can both
promote cell survival. Subsequent exper-
iments suggested that activation of the
MAPK but not the Akt pathway conferred
a partial metastatic advantage to low
Ezrin-expressing cells, suggesting that
Ezrin may control multiple pathways that
contribute to metastasis. Indeed, Yu et al.
provided a link between the activity of the
small GTPase Rho and Ezrin-dependent
metastatic potential, consistent with the
firmly established reciprocal relationship
between the ERM proteins and Rho
activity. Through its effects on the actin
cytoskeleton and cell morphology, Rho is
known to control cell adhesion and motil-
ity. As pointed out by both groups, Ezrin
likely functions at the intersection of mul-
tiple signaling pathways.
It is interesting to note some com-
mon features shared by the two types of
experimental neoplasia used in these
two studies. The ERM proteins have
been best studied in epithelial cells, and
much less is known about their function
in mesenchymal cells such as myocytes
and osteoblasts, the likely precursors of
RMS and OSA. In the RMS model, trans-
genic overexpression of hepatocyte
growth factor (HGF), combined with
Ink4a/Arf-deficiency, drives tumorigene-
sis. It is notable that nearly 100% of
human osteosarcomas exhibit aberrant
HGF signaling; evidence for deregulated
HGF signaling in dog OSA has also been
found (Birchmeier et al., 2003; MacEwen
et al., 2003). Many studies have linked
HGF and its receptor, c-met, to 
the process of tumor metastasis.
Interestingly, Ezrin is a well-known effec-
tor of HGF and is required for HGF-
induced migration and tubulogenesis
(Bretscher et al., 2002). Indeed, Yu et al.
demonstrated that Ezrin is required for
branching morphogenesis by RMS cells
in a similar assay. Thus, Ezrin may be
specifically required for HGF/c-Met-
associated tumor metastasis in this and
other models.
Both RMS and OSA typically occur
in pediatric and young adult patients,
and are likely to arise from altered differ-
entiation of precursor cells. Consistent
with this possibility, Yu et al. also found
that Six-1, a transcription factor known to
control migration of muscle precursor
cells during early myogenesis, is also
markedly overexpressed in metastatic
RMS cell lines. Interestingly, experimen-
tal overexpression of Six-1 led to
increased Ezrin expression. Perhaps
Ezrin functions to promote muscle pre-
cursor migration during normal develop-
ment—a process that is known to be
HGF-dependent (Birchmeier et al.,
2003).
Finally, one must consider a possible
link between Ezrin and Merlin, the prod-
uct of the NF2 tumor suppressor gene.
Loss of NF2 leads to the development of
a variety of tumors in humans and mice
(McClatchey, 2003). Notably, Nf2 mutant
mice are particularly predisposed to
developing highly metastatic osteosarco-
mas (Figure 1). Overlapping subcellular
localization, common interacting part-
ners, and physical interaction between
Ezrin and Merlin suggest a functional
relationship. Could Ezrin overexpression
inhibit Merlin function, thereby promoting
tumor metastasis? Conversely, could loss
of Merlin cause Ezrin activation? Future
studies of Ezrin’s role in tumor metastasis
are likely to yield important insight into
this interesting family of proteins. The
identification of Ezrin as a metastatic
determinant suggests that therapeutic
strategies aimed at inhibiting Ezrin func-
tion may be useful in combating this com-
plex and devastating aspect of cancer.
Marcello Curto and 
Andrea I. McClatchey*
MGH Cancer Center and Harvard 




Bernards, R., and Weinberg, R.A. (2002). Nature
418, 823.
Birchmeier, C., Birchmeier, W., Gherardi, E., and
Vande Woude, G.F. (2003). Nat. Rev. Mol. Cell
Biol. 4, 915–925.
Bretscher, A., Edwards, K., and Fehon, R.G.
(2002). Nature Rev. Mol. Cell Biol. 3, 586–599.
Hynes, R.O. (2003). Cell 113, 821–823.
Khanna, C., Khan, J., Nguyen, P., Prehn, J.,
Caylor, J., Yeung, C., Trepel, J., Meltzer, P., and
Helman, L. (2001). Cancer Res. 61, 3750–3759.
Khanna, C., Wan, X., Bose, S., Cassaday, R.,
Olomu, O., Mendoza, A., Yeung, C., Gorlick, R.,
Hewitt, S.M., and Helman, L.J. (2004). Nat. Med.
10, 182–186.
MacEwen, E.G., Kutzke, J., Carew, J., Pastor, J.,
Schmidt, J.A., Tsan, R., Thamm, D.H., and
Radinsky, R. (2003). Clin. Exp. Metastasis 20,
421–430.
McClatchey, A.I. (2003). Nature Rev. Cancer 3,
877–882.
Nestl, A., Von Stein, O.D., Zatloukal, K., Thies,
W.G., Herrlich, P., Hofmann, M., and Sleeman,
J.P. (2001). Cancer Res. 61, 1569–1577.
Yu, Y., Khan, J., Khanna, C., Helman, L., Meltzer,
P.S., and Merlino, G. (2004). Nat. Med. 10,
175–181.
P R E V I E W S
